Join us for a Free Webinar on May 22

Space is limited.
Reserve your Webinar seat now at:
https://www1.gotomeeting.com/register/737050536

In an average pregnancy, 13% of the free DNA in the peripheral circulation of the mother originates from the fetus. This is sufficient that non-invasive detection of fetal aneuploidies by DNA sequencing will soon become routine. It is also possible to reconstruct most of the fetal genome sequence by sampling the DNA in the mothers blood, but this is still too costly for routine use. The methods developed to analyze these mixed maternal fetal DNA samples should be applicable to other problems in DNA mixture sequencing.

The presentation will cover:

• Plasma DNA as a biomarker
• Estimation of the fraction of fetal DNA in maternal plasma
• Non-invasive prenatal detection of trisomy 21
• Non-invasive whole genome sequencing on an unborn fetus

Sequenom, Inc. designs, develops, manufactures and markets innovative technology, instrumentation and tests that target and serve discovery and clinical research, and clinical molecular diagnostics markets. Applications include translational research, oncology, agricultural genomics and in vitro diagnostics for prenatal and retinal disorders.

Presenter:
Dr. Charles Cantor, Chief Scientific Officer, Sequenom, Inc.

Dr. Charles R. Cantor, Ph.D. is the Founder of Sequenom Inc. and has been its Chief Scientific Officer since August 1998. Dr. Cantor is a Consultant to more than 16 biotech firms. From 1992 to August 1998, Dr. Cantor served as the Chairman and a Professor in the Department of Biomedical Engineering and Director of the Center for Advanced Biotechnology at Boston University.

After registering you will receive a confirmation email containing information about joining the Webinar.

System Requirements
PC-based attendees
Required: Windows® 7, Vista, XP or 2003 Server

Macintosh®-based attendees
Mac OS® X 10.5 or newer